RO7200220
- Generic Name
- RO7200220
- Drug Type
- Biotech
- Background
RO7200220 is a recombinant fully humanized anti-IL 6 monoclonal antibody.
A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema
Phase 1
Completed
- Conditions
- Diabetic Macular EdemaUveitic Macular Edema
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT06771271
- Locations
- 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retina Institute of California Medical Group d/b/a Acuity Eye Group, Palm Desert, California, United States
🇺🇸Byers Eye Insitute at Stanford, Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath